Debiopharm


Debiopharm Group is a family-owned biopharmaceutical group of companies active in drug development and manufacturing of proprietary drugs, diagnostics, and investments, headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay.

Subsidiaries

The group works through its subsidiaries:
As of 2010 two drugs had reached the market through its efforts: oxaliplatin for the treatment of cancer, and depot formulations of triptorelin, a gonadotropin-releasing hormone agonist that is approved to treat advanced prostate cancer.
In 2017, Debiopharm acquired a phase 2 drug candidate from ImmunoGen that intends to target Non-Hodgkin lymphoma.